GlaxoSmithKline PLC (GSK)

44.29
NYSE : Health Care
Prev Close 44.16
Day Low/High 44.10 / 44.38
52 Wk Low/High 37.20 / 45.58
Avg Volume 3.03M
Exchange NYSE
Shares Outstanding 2.46B
Market Cap 108.59B
EPS 0.50
P/E Ratio 25.38
Div & Yield 1.95 (4.40%)

Latest News

Still Waiting for the All-Clear on FANG

Resist the urge to buy; their time will come again.

European Stocks See New Peaks in Volatile Session

European Stocks See New Peaks in Volatile Session

While causing upset among politicians and some business leaders, President Donald Trump's withdrawal of the U.S. from the Paris Agreement helped boost stock prices across the chemicals and automotive sectors.

GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment

GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment

Glaxo was boosted Friday after its HIV joint-venture filed an application in the U.S. and EU for a new combination tablet, in a continued push for dominance in the field

GlaxoSmithKline Surges to New Highs

GlaxoSmithKline Surges to New Highs

GSK is trading at 2017 highs today as investors continue to aggressively accumulate shares.

European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data

European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data

European stocks were mixed Wednesday as investors responded to a mixture of M&A speculation, economic data and other individual company news.

Bristol-Myers Hookup Boosts Array BioPharma

Bristol-Myers Hookup Boosts Array BioPharma

Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.

European Stocks Fall as Politics Takes Center Stage

European Stocks Fall as Politics Takes Center Stage

European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.

GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead

GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead

GlaxoSmithKline shares outperformed the market Tuesday after clinical trials data for Gilead's Bictegravir HIV treatment appeared to reduce the threat of a superior rival to GSK's Dolutegravir.

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.

Analysts' Actions -- Cloudera, Carvana, Domino's, McKesson and More

Analysts' Actions -- Cloudera, Carvana, Domino's, McKesson and More

Here are Tuesday's top research calls, including new coverage of recent IPOs Cloudera and Carvana, as well as new analyst coverage of Domino's Pizza and an upgrade of McKesson.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKFS, CWAY, DE, EZPW, GSK, LMNX Downgrades: AMC, ESRT, MYOK, WERN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Hikma Trims Full-Year Revenue Guidance After Advair Diskus Delay

Hikma Trims Full-Year Revenue Guidance After Advair Diskus Delay

Hikma Pharmaceuticals lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product.

Huge Downgrades Loom Over Hikma Pharmaceuticals

Huge Downgrades Loom Over Hikma Pharmaceuticals

Hikma could get hit with sizeable downgrades Friday when it updates the market with new guidance in the wake of the FDA's rejection of its generic Advair Diskus product

GlaxoSmithKline Could Buy Out Partner Novartis

GlaxoSmithKline Could Buy Out Partner Novartis

Novartis holds a 36.5% stake in the healthcare company.

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of "frustration".

Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval

Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval

Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.

European Stocks See Mixed Session as U.K.'s FTSE Leads

European Stocks See Mixed Session as U.K.'s FTSE Leads

European stock markets were mixed Wednesday's as investors responded to yet another raft earnings reports, company statements and comments from policy makers across the continent.

Mylan Unhappy With FDA Standards for Asthma Drug

Mylan Unhappy With FDA Standards for Asthma Drug

Earlier this year the FDA sent Mylan a letter saying it would not approve its drug.

Hikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair

Hikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair

Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.

Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive results from the innovative Salford Lung Study (SLS) in asthma, carried out amongst 4,233 patients treated by their own General...

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

How Far Into the Drug Pipeline Should the FTC Reach?

How Far Into the Drug Pipeline Should the FTC Reach?

Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.

How Much Did the YouTube Ad Boycott Cost Google in the First Quarter?

How Much Did the YouTube Ad Boycott Cost Google in the First Quarter?

Advertisers appear to be coming back to Alphabet's YouTube, but analysts are still likely to be skeptical on the company's Thursday earnings call.

European Benchmarks Lifted by Sluice of Strong Corporate Earnings

European Benchmarks Lifted by Sluice of Strong Corporate Earnings

From automakers to financials, strong corporate earnings numbers helped to boost major European benchmarks Wednesday, although stocks in Southern Europe fell on concerns over bank capital

Glaxo Stock Slumps as Investors Eye Advair Generics

Glaxo Stock Slumps as Investors Eye Advair Generics

Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017

GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place

GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place

GlaxoSmithKline posted stronger-than-expected first quarter earnings and kept its full year profit and revenue figures in place as it awaits potential rivals to is Advair respiratory treatment.line

Can Anything Dent the Fox News Brand?

Can Anything Dent the Fox News Brand?

Two sexual harassment scandals might devastate other brands, but not so with Fox News.